Literature DB >> 31040230

Precision tyrosine kinase inhibitor dosing in chronic myeloid leukemia?

Giuseppe Saglio1, Carmen Fava1, Robert Peter Gale2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31040230      PMCID: PMC6518890          DOI: 10.3324/haematol.2018.214445

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  22 in total

Review 1.  Biomarker: Predictive or Prognostic?

Authors:  Karla V Ballman
Journal:  J Clin Oncol       Date:  2015-09-21       Impact factor: 44.544

2.  Phase III clinical trials that integrate treatment and biomarker evaluation.

Authors:  Boris Freidlin; Zhuoxin Sun; Robert Gray; Edward L Korn
Journal:  J Clin Oncol       Date:  2013-04-08       Impact factor: 44.544

3.  Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.

Authors:  Andreas Hochhaus; Richard A Larson; François Guilhot; Jerald P Radich; Susan Branford; Timothy P Hughes; Michele Baccarani; Michael W Deininger; Francisco Cervantes; Satoko Fujihara; Christine-Elke Ortmann; Hans D Menssen; Hagop Kantarjian; Stephen G O'Brien; Brian J Druker
Journal:  N Engl J Med       Date:  2017-03-09       Impact factor: 91.245

4.  Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.

Authors:  Simona Soverini; Sabrina Colarossi; Alessandra Gnani; Gianantonio Rosti; Fausto Castagnetti; Angela Poerio; Ilaria Iacobucci; Marilina Amabile; Elisabetta Abruzzese; Ester Orlandi; Franca Radaelli; Fabrizio Ciccone; Mario Tiribelli; Roberto di Lorenzo; Clementina Caracciolo; Barbara Izzo; Fabrizio Pane; Giuseppe Saglio; Michele Baccarani; Giovanni Martinelli
Journal:  Clin Cancer Res       Date:  2006-12-15       Impact factor: 12.531

5.  Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV.

Authors:  Rüdiger Hehlmann; Martin C Müller; Michael Lauseker; Benjamin Hanfstein; Alice Fabarius; Annette Schreiber; Ulrike Proetel; Nadine Pletsch; Markus Pfirrmann; Claudia Haferlach; Susanne Schnittger; Hermann Einsele; Jolanta Dengler; Christiane Falge; Lothar Kanz; Andreas Neubauer; Michael Kneba; Frank Stegelmann; Michael Pfreundschuh; Cornelius F Waller; Karsten Spiekermann; Gabriela M Baerlocher; Gerhard Ehninger; Dominik Heim; Hermann Heimpel; Christoph Nerl; Stefan W Krause; Dieter K Hossfeld; Hans-Jochem Kolb; Joerg Hasford; Susanne Saußele; Andreas Hochhaus
Journal:  J Clin Oncol       Date:  2013-12-02       Impact factor: 44.544

6.  Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia.

Authors:  Domenico Russo; Giovanni Martinelli; Michele Malagola; Cristina Skert; Simona Soverini; Ilaria Iacobucci; Antonio De Vivo; Nicoletta Testoni; Fausto Castagnetti; Gabriele Gugliotta; Diamante Turri; Micaela Bergamaschi; Michela Bergamaschi; Patrizia Pregno; Ester Pungolino; Fabio Stagno; Massimo Breccia; Bruno Martino; Tamara Intermesoli; Carmen Fava; Elisabetta Abruzzese; Mario Tiribelli; Catia Bigazzi; Bruno Mario Cesana; Gianantonio Rosti; Michele Baccarani
Journal:  Blood       Date:  2013-05-15       Impact factor: 22.113

7.  The incidence of leukemia, lymphoma and multiple myeloma among atomic bomb survivors: 1950-2001.

Authors:  Wan-Ling Hsu; Dale L Preston; Midori Soda; Hiromi Sugiyama; Sachiyo Funamoto; Kazunori Kodama; Akiro Kimura; Nanao Kamada; Hiroo Dohy; Masao Tomonaga; Masako Iwanaga; Yasushi Miyazaki; Harry M Cullings; Akihiko Suyama; Kotaro Ozasa; Roy E Shore; Kiyohiko Mabuchi
Journal:  Radiat Res       Date:  2013-02-11       Impact factor: 2.841

8.  Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease.

Authors:  Susan Branford; Paul Wang; David T Yeung; Daniel Thomson; Adrian Purins; Carol Wadham; Nur Hezrin Shahrin; Justine E Marum; Nathalie Nataren; Wendy T Parker; Joel Geoghegan; Jinghua Feng; Naranie Shanmuganathan; Martin C Mueller; Christian Dietz; Doris Stangl; Zoe Donaldson; Haley Altamura; Jasmina Georgievski; Jodi Braley; Anna Brown; Christopher Hahn; Ieuan Walker; Soo-Hyun Kim; Soo-Young Choi; Sa-Hee Park; Dong-Wook Kim; Deborah L White; Agnes S M Yong; David M Ross; Hamish S Scott; Andreas W Schreiber; Timothy P Hughes
Journal:  Blood       Date:  2018-07-02       Impact factor: 22.113

9.  Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV.

Authors:  Christian Michel; Andreas Burchert; Andreas Hochhaus; Susanne Saussele; Andreas Neubauer; Michael Lauseker; Stefan W Krause; Hans-Jochem Kolb; Dieter Kurt Hossfeld; Christoph Nerl; Gabriela M Baerlocher; Dominik Heim; Tim H Brümmendorf; Alice Fabarius; Claudia Haferlach; Brigitte Schlegelberger; Leopold Balleisen; Maria-Elisabeth Goebeler; Mathias Hänel; Anthony Ho; Jolanta Dengler; Christiane Falge; Robert Möhle; Stephan Kremers; Michael Kneba; Frank Stegelmann; Claus-Henning Köhne; Hans-Walter Lindemann; Cornelius F Waller; Karsten Spiekermann; Wolfgang E Berdel; Lothar Müller; Matthias Edinger; Jiri Mayer; Dietrich W Beelen; Martin Bentz; Hartmut Link; Bernd Hertenstein; Roland Fuchs; Martin Wernli; Frank Schlegel; Rudolf Schlag; Maike de Wit; Lorenz Trümper; Holger Hebart; Markus Hahn; Jörg Thomalla; Christof Scheid; Philippe Schafhausen; Walter Verbeek; Michael J Eckart; Winfried Gassmann; Michael Schenk; Peter Brossart; Thomas Wündisch; Thomas Geer; Stephan Bildat; Erhardt Schäfer; Joerg Hasford; Rüdiger Hehlmann; Markus Pfirrmann
Journal:  Haematologica       Date:  2018-12-04       Impact factor: 9.941

Review 10.  European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

Authors:  Michele Baccarani; Michael W Deininger; Gianantonio Rosti; Andreas Hochhaus; Simona Soverini; Jane F Apperley; Francisco Cervantes; Richard E Clark; Jorge E Cortes; François Guilhot; Henrik Hjorth-Hansen; Timothy P Hughes; Hagop M Kantarjian; Dong-Wook Kim; Richard A Larson; Jeffrey H Lipton; François-Xavier Mahon; Giovanni Martinelli; Jiri Mayer; Martin C Müller; Dietger Niederwieser; Fabrizio Pane; Jerald P Radich; Philippe Rousselot; Giuseppe Saglio; Susanne Saußele; Charles Schiffer; Richard Silver; Bengt Simonsson; Juan-Luis Steegmann; John M Goldman; Rüdiger Hehlmann
Journal:  Blood       Date:  2013-06-26       Impact factor: 22.113

View more
  1 in total

1.  Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP.

Authors:  Michele Baccarani; Elisabetta Abruzzese; Vincenzo Accurso; Francesco Albano; Mario Annunziata; Sara Barulli; Germana Beltrami; Micaela Bergamaschi; Gianni Binotto; Monica Bocchia; Giovanni Caocci; Isabella Capodanno; Francesco Cavazzini; Michele Cedrone; Marco Cerrano; Monica Crugnola; Mariella D'Adda; Chiara Elena; Carmen Fava; Paola Fazi; Claudio Fozza; Sara Galimberti; Valentina Giai; Antonella Gozzini; Gabriele Gugliotta; Alessandra Iurlo; Gaetano La Barba; Luciano Levato; Alessandro Lucchesi; Luigia Luciano; Francesca Lunghi; Monia Lunghi; Michele Malagola; Roberto Marasca; Bruno Martino; Angela Melpignano; Maria Cristina Miggiano; Enrico Montefusco; Caterina Musolino; Fausto Palmieri; Patrizia Pregno; Davide Rapezzi; Giovanna Rege-Cambrin; Serena Rupoli; Marzia Salvucci; Rosaria Sancetta; Simona Sica; Raffaele Spadano; Fabio Stagno; Mario Tiribelli; Simona Tomassetti; Elena Trabacchi; Massimiliano Bonifacio; Massimo Breccia; Fausto Castagnetti; Fabrizio Pane; Domenico Russo; Giuseppe Saglio; Simona Soverini; Paolo Vigneri; Gianantonio Rosti
Journal:  Blood Adv       Date:  2019-12-23
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.